Mumbai, India—Nutriventia, a brand from Inventia Healthcare, has announced a new study on its branded turmeric ingredient TurmXTRA 60N, published in Clinical Pharmacology: Advances and Applications.
The 90-day, randomized, double-blind, placebo-controlled, clinical trial was conducted in 96 healthy adults who experienced chronic knee pain following physical exertion. The findings: The patients who took 250mg/day of the turmeric extract saw a pain reduction 2.5 times greater than those who took placebo. It also improved the amount of time required for participants to perform an 80m fast-paced walk test and a 9-step stair-climb test. The researchers further noted that the extract was well-tolerated and found to be safe for human consumption.
“This study is pivotal since it showcases the benefits of a small dose of TurmXTRA 60N, that in healthy subjects and as more people become active, a supplement that helps preserve knee structure and function we feel will be highly sought after,” said Anand Godbole, Inventia Assistant Vice President of Marketing & Strategy, in the press release.